CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed...
- Mechanism
- Curator reviewed
CMLVAX100 is a BCR-ABL peptide vaccine designed to reduce persistent disease in patients with chronic myeloid leukemia (CML) whom have had stable disease during conventional therapy. Targeting the BCR-ABL breakpoint with vaccine based medicines is an important approach to those with detectable CML. Breakthrough has optimized the components of VAX100 to enhance its activity.
- Primary indication
- Investigated for use/treatment in leukemia (myeloid).Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with CMLVAX100, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account